Brentuximab vedotin in the treatment of anaplastic large cell lymphoma Case Study

Author: Dr. Farid Azadian, University of Ottawa

Reviewer: Dr. Kevin Imrie, Odette Cancer Centre (Sunnybrook Hospital)

Learning Objectives

At the end of the self-assessment module, participants will be able to:

• Describe the treatment options for ALCL
• Describe the mechanism of action of Brentuximab vedotin
• Explain the efficacy and safety profile of Brentuximab vedotin in the treatment of ALCL

CHS Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None